The expression of uPAR, together with Bmi-1, ABCG2 and CD133, confers chemoresistance to cisplatin and pemetrexed to the MPM cell lines, identifying a population of putative drug-resistant CSC to be, possibly, targeted in anti-cancer therapies (Cortes-Dericks et al., 2010). The gene discussed is PLAUR; the disease is cancer.